JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

Search

Artivion Inc

Cerrado

SectorSalud

45.73 0.64

Resumen

Variación precio

24h

Actual

Mínimo

44.15

Máximo

45.96

Métricas clave

By Trading Economics

Ingresos

21M

21M

Ventas

14M

113M

Margen de beneficio

18.536

Empleados

1,600

EBITDA

14M

16M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

-0.24% downside

Dividendos

By Dow Jones

Próximas Ganancias

6 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

603M

2.1B

Apertura anterior

45.09

Cierre anterior

45.73

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

156 / 373 Clasificación en Healthcare

Artivion Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

3 nov 2025, 21:44 UTC

Ganancias

Vertex Pharmaceuticals Revenue Climbs on Demand for Cystic Fibrosis Drugs

3 nov 2025, 23:44 UTC

Charlas de Mercado

Nikkei May Rise on Weaker Yen, Hopes for Govt Econ Steps -- Market Talk

3 nov 2025, 23:34 UTC

Charlas de Mercado

Gold Edges Lower Amid Lingering Worry Over China's Ending of Tax Incentive -- Market Talk

3 nov 2025, 23:28 UTC

Ganancias

Palantir Revenue Hits Another Record as Defense Work Booms -- 2nd Update

3 nov 2025, 23:24 UTC

Ganancias

Correct: Grab Holdings Sees FY2025 Adj Ebitda $490M-$500.0M, Higher Than $460M-$480M Projected in 2Q >GRAB

3 nov 2025, 23:14 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Global Equities Roundup: Market Talk

3 nov 2025, 23:14 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Deterra's Next CEO Might Bring New Approach to Deals -- Market Talk

3 nov 2025, 23:12 UTC

Ganancias

Grab Holdings Sees FY2025 Adj Ebitda $490-$500.0M, Higher Than $460M-$480M Projected in 2Q >GRAB

3 nov 2025, 23:09 UTC

Ganancias

Grab Holdings 3Q 2Q Adj EBITDA $136.0M Vs. $90.0M>GRAB

3 nov 2025, 23:09 UTC

Ganancias

Grab Holdings 3Q Net $17.0M Vs. Net $15.0M >GRAB

3 nov 2025, 23:09 UTC

Ganancias

Grab Holdings 3Q Rev $873.0M Vs. $716.0M >GRAB

3 nov 2025, 23:06 UTC

Charlas de Mercado
Ganancias

Palantir Execs Forecast Future of U.S. Workers In AI World -- Market Talk

3 nov 2025, 22:36 UTC

Charlas de Mercado
Ganancias

Palantir's U.S. Commercial Business Booms as It Expands AI -- Market Talk

3 nov 2025, 22:31 UTC

Ganancias

Franco-Nevada 3Q EPS $1.49 >FNV

3 nov 2025, 22:31 UTC

Ganancias

Franco-Nevada 3Q Rev $487.7M >FNV

3 nov 2025, 22:24 UTC

Charlas de Mercado

Xero Bulls Expect Improving U.S. Momentum in 1H -- Market Talk

3 nov 2025, 22:19 UTC

Adquisiciones, fusiones, absorciones

Starbucks Agrees to Sell Stake in China Business -- WSJ

3 nov 2025, 21:59 UTC

Charlas de Mercado

RBA Set To Keep Rates On Hold; Remain Data Dependent -- Market Talk

3 nov 2025, 21:54 UTC

Charlas de Mercado
Ganancias

Westpac's Tech Challenge Keeps Jefferies Cautious -- Market Talk

3 nov 2025, 21:54 UTC

Charlas de Mercado
Ganancias

Global Equities Roundup: Market Talk

3 nov 2025, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

3 nov 2025, 21:49 UTC

Ganancias

Palantir Revenue Hits Another Record as Defense Work Booms -- Update

3 nov 2025, 21:40 UTC

Ganancias

Barry Diller's IAC Inks AI Deal With Microsoft. That Isn't Why the Stock Is Sliding. -- Barrons.com

3 nov 2025, 21:31 UTC

Charlas de Mercado

Mexican Manufacturing Indexes Pick Up in October -- Market Talk

3 nov 2025, 21:19 UTC

Ganancias

Palantir Revenue Hits Another Record as Defense Work Booms -- WSJ

3 nov 2025, 21:11 UTC

Adquisiciones, fusiones, absorciones

Pfizer Reports Earnings Tuesday. Management Has Big Questions to Answer. -- Barrons.com

3 nov 2025, 21:11 UTC

Ganancias

Diamondback Energy: Increasing Full Yr Oil Production Guidance to 495-498 MBO/d and Increasing Annual BOE Guidance to 910-920 MBOE/d >FANG

3 nov 2025, 21:07 UTC

Ganancias

Palantir Technologies: Raising 2025 U.S. Comml Rev Guidance to in Excess of $1.433B, Representing a Growth Rate of at Least 104% >PLTR

3 nov 2025, 21:05 UTC

Ganancias

Vertex Pharmaceutic Sees 2025 Rev $11.9B-$12B >VRTX

3 nov 2025, 21:05 UTC

Ganancias

Palantir Technologies 3Q Net $475.6M >PLTR

Comparación entre iguales

Cambio de precio

Artivion Inc Esperado

Precio Objetivo

By TipRanks

-0.24% caída

Estimación a 12 meses

Media 45.26 USD  -0.24%

Máximo 50 USD

Mínimo 38.8 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Artivion Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

7 ratings

6

Comprar

1

Mantener

0

Vender

Sentimiento

By Acuity

156 / 373 Clasificación en Salud

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Artivion Inc

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.
help-icon Live chat